BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed (available at: http://www.ncbi.nlm.nih.gov/pubmed/23325450 ) and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February 2013. The publication, titled "Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies," is co-authored by Harold E. Bays, M.D. (Medical Director, Louisville Metabolic and Atherosclerosis Research Center), Christie M. Ballantyne, M.D. (Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, TX), and Amarin scientists. The publication reports the effects of Vascepa ® (icosapent ethyl) capsules, alone and in combination with statin therapies, on inflammatory markers associated with cardiovascular disease and atherosclerosis in hypertriglyceridemic patients. In addition to the previously reported favorable lipid effects of Vascepa on hypertriglyceridemic patients in the MARINE and ANCHOR studies, this newly published analysis of these studies shows that Vascepa 4g/day significantly decreased levels of several inflammatory markers relative to placebo, including oxidized low-density lipoprotein (Ox-LDL), lipoprotein-associated phospholipase A2 (Lp-PLA 2), and high sensitivity C-reactive protein (hsCRP). "Statins are known to decrease hsCRP levels, and subjects in both MARINE and ANCHOR who received statin therapy were on stable therapy prior to administration of Vascepa," stated Steve Ketchum, Ph.D., President of Research and Development for Amarin. "The effects of Vascepa on inflammatory markers described in this publication were in addition to effects already achieved with statins. It is of interest that in ANCHOR, Vascepa decreased hsCRP more in higher-efficacy statin regimens, which is consistent with the previously reported ANCHOR findings of higher triglyceride reductions in patients with higher-efficacy statin regimens."